Yahoo · Sep 1, 2026
Reckitt Gets a Baby Formula Break
Shares jumped after Mead Johnson won a key US trial, easing one of the biggest legal clouds hanging over the group.
OTC · RBGLY
Consumer Defensive · Household & Personal Products
$13.77
Up+$0.18 (+1.32%)
Updated Sep 11, 2026, 6:27 AM
SID Score
5.3/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
RBGLY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning RBGLY.
RBGLY research
Company profile and research snapshot.
RECKITT BENCKISR GP S/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 16, 2026 | Jefferies | Hold | — |
| May 15, 2026 | RBC Capital Markets | Neutral | — |
| May 12, 2026 | Jefferies | Hold | — |
| Apr 28, 2026 | Deutsche | Hold | — |
| Apr 24, 2026 | Berenberg Bank | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 1, 2026
Shares jumped after Mead Johnson won a key US trial, easing one of the biggest legal clouds hanging over the group.
Yahoo · Sep 1, 2026
Shares in Reckitt Benckiser Group PLC (LSE:RKT, OTCQX:RBGLY), the consumer goods company behind Dettol and Nurofen, rose over 4% on Tuesday as investors digested a legal win for its Mead Johnson unit and a JP Morgan upgrade to overweight. The upgrade came in a wider note on European consumer...
SeekingAlpha · Aug 7, 2026
Reckitt Benckiser (RKT) rated Buy: 21% peer discount, strong FY2025 growth/margins, and litigation risk update. Reda here for a detailed analysis.
SeekingAlpha · Jul 31, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning RBGLY.